Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera

Blood Cancer Journal - Tập 8 Số 12
Tiziano Barbui1, Valerio De Stefano2, Arianna Ghirardi1, Arianna Masciulli1, Guido Finazzi3, Alessandro M. Vannucchi4
1FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy
2Institute of Hematology, Catholic University, Roma, Italy
3USC Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
4Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative neoplasms (CRIMM), AOU Careggi, University of Florence, Florence, Italy

Tóm tắt

Từ khóa


Tài liệu tham khảo

Barbui, T., Finazzi, G. & Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood 122, 2176–2184 (2013).

Marchioli, R. et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 368, 22–33 (2013).

Landolfi, R. et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 350, 114–124 (2004).

Barbui, T. et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32, 1057–1069 (2018).

Tefferi, A., Vannucchi, A. M. & Barbui, T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 8, 3 (2018).

Kaplan, M. E. et al. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin. Hematol. 23, 167–171 (1986).

Vannucchi, A. M. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 1670–1671 (2015).

Spivak, J. L. Myeloproliferative neoplasms. N. Engl. J. Med. 376, 2168–2181 (2017).

Barbui, T. et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am. J. Hematol. 92, 1131–1136 (2017).

Cerquozzi, S. et al. Risk factors for arterial versus venous thrombosis inpolycythemia vera: a single center experience in 587 patients. Blood Cancer J. 7, 662 (2017).

Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46, 399–424 (2011).

Maugeri, N. et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J. Thromb. Haemost. 4, 2593–2598 (2006).

Wendelboe, A. M. & Raskob, G. E. Global burden of thrombosis: epidemiologic aspects. Circ. Res. 118, 1340–1347 (2016).